Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple bNAb Combination (PGT121, VRC07-523LS, PGDM1400) in HIV
NCT03721510Phase 2Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Dec 2018
- Primary completion
- Oct 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of PGT121, VRC07-523LS and PGDM1400LS in human immunodeficiency virus infection (HIV) (3 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Proportion of volunteers with moderate or greater reactogenicity, Proportion of volunteers with adverse events (AEs) at 56 days and 5 more. Started Dec 2018; status: completed.
02
Drugs
PGT121VRC07-523LSPGDM1400LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03721510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721510.